President Bob Myers said PECO continues to see “high demand for necessity-based retail,” with strong leasing activity and record-high inline occupancy. The company executed 1,026 leases totaling approximately 6 million square feet in 2025. Portfolio occupancy ended the year at 97.3% leased , with anchor occupancy at 98.7% and inline leased occupancy at a record 95.1% , up 30 basis points sequentially. The portfolio retention rate was 93% at year-end.CFO John Caulfield detailed 2026 guidance, including net i ...

PJT Partners (NYSE:PJT) Q4 2025 Earnings call February 03, 2026 08:30 AM ET Company ParticipantsAlex Bond - VP of Equity ResearchBrendan O'Brien - SVPDevin Ryan - Director of Financial Technology ResearchHelen Meates - CFOPaul Taubman - Chairman and CEOSharon Pearson - Head of Investor RelationsConference Call ParticipantsBrennan Hawken - Senior Equity Research AnalystJames Mitchell - Senior Equity AnalystMichael Brown - Managing Director and Senior Equity Research AnalystNone - AnalystOperatorGood day and ...

Financial Data and Key Metrics Changes - For Q4 2025, the company generated adjusted net trading income (NT) of $9.7 million per day, totaling $613 million, marking the highest quarterly total since Q1 2021 [7] - The full year 2025 adjusted NT was $8.6 million per day, or $2.1 billion in total [7] - Adjusted EBITDA for Q4 was $442 million, representing a 72% margin, while for the full year, it was $1.4 billion with a 65% margin [8] - Adjusted EPS for Q4 was $1.85, and for the full year, it was $5.73, both representing highs since 2021 [8] Business Line Data and Key Metrics Changes - Market Making reported NT of $7.8 million per day for Q4 and $6.7 million per day for the full year 2025 [7] - Virtu Execution Services (VES) reached $2 million per day for Q4 and $1.9 million per day for the full year [7] - VES experienced its seventh consecutive quarter of increased NT, indicating substantial progress and strong client engagement [8] Market Data and Key Metrics Changes - The favorable operating environment contributed to elevated volumes and strong execution across both operating segments [8] - The company noted increased volatility and higher equity share volumes as underlying drivers for performance [11] Company Strategy and Development Direction - The company plans to grow trading by investing in infrastructure, acquiring talent, and expanding its capital base, with a broad effort across the firm [5][32] - The focus is on increasing the total trading capital and dynamically responding to market opportunities [32] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the favorable operating environment and the potential for continued growth due to favorable market conditions [11][25] - The company aims to maintain a quarterly dividend of $0.24 per share while expanding its capital base [9] Other Important Information - The company increased its invested capital by $625 million in 2025, with an average return of 100% over the year [9] - The cash compensation ratio for the full year 2025 was at 19%, reflecting the focus on retaining and acquiring top talent [9] Q&A Session Summary Question: Did the strong performance come from areas outside of equities? - Management indicated that the favorable operating environment, including increased volatility and equity share volumes, contributed to performance across various asset classes, not just equities [11][12] Question: What is Virtu's exposure to the ETF market? - Management stated that Virtu is a large player in the ETF market, but quantifying the specific impact is challenging [15][16] Question: What are the top strategic priorities for 2026? - The focus is on broad growth initiatives across the firm, increasing trading capital, and investing in infrastructure and talent [32] Question: How much incremental capital was deployed during the quarter? - The company deployed over $600 million in incremental capital, with $450 million in the second half of the year [34] Question: Will innovations around clearing and settlement impact Virtu's PNL? - Management believes that while the exact economic impact is uncertain, increased complexity in the market can provide a competitive advantage [39]

Financial Data and Key Metrics Changes - The company reported net earnings of $83 million or $0.64 per share for the fourth quarter, with an annualized return on average assets of 1.34% and an adjusted return on average tangible common equity of 17.6% [3][10] - Pre-provision net revenue reached a record $111 million, representing an ROA of 1.78% [3][10] - Revenue increased to a record $226 million, driven by record net interest income of $197 million and non-interest income of $28.3 million [10] Business Line Data and Key Metrics Changes - The commercial loan team generated total new loan production of $3.2 billion in 2025, with net commercial loan growth of 5.5% for the year [4] - Average non-interest-bearing deposits grew by 2% annualized, contributing to the overall growth in core deposits, which increased by $260 million or 6.6% annualized [5] - Non-interest income increased to $28.3 million, with significant contributions from the insurance agency and SBA loan sales [7][8][15] Market Data and Key Metrics Changes - The company experienced a favorable improvement in non-performing assets, which declined to 0.32% of total assets [6][14] - The average cost of total deposits decreased to 2.1%, while the total cost of funds decreased to 2.34% [13] Company Strategy and Development Direction - The company plans to continue investing in revenue-producing talent across various platforms, including middle market banking, treasury management, SBA, wealth management, and insurance [8][9] - A core system conversion is scheduled for the fall of 2026 to enhance scalability and digital capabilities [9][84] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining growth momentum and improving profitability, with expectations for loans and deposits to grow in the 4%-6% range for 2026 [18] - The competitive landscape for deposits remains challenging, but the company is focused on maintaining its core model and capturing market share [36] Other Important Information - The company announced a new share repurchase authorization allowing for the buyback of an additional 2 million shares [8] - The tangible book value per share increased by 3.8% to $15.70, and the tangible common equity ratio rose to 8.48% [17] Q&A Session Summary Question: Inquiry about the effective tax rate and tax credit investments - Management clarified that the effective tax rate is projected to be approximately 29% for 2026, with benefits from tax credit investments realized throughout the year [23][25] Question: Discussion on capital deployment priorities - Management indicated that organic growth remains the primary focus, with potential considerations for dividends and investments in insurance and wealth platforms [26][27] Question: Insights on deposit competition and its impact - Management acknowledged heightened competition for deposits but emphasized their strong performance in core deposits and the ability to capture market share [36] Question: Trends in the commercial real estate (CRE) market - Management noted a healthier CRE market and expressed no interest in acquiring portfolios from competitors, focusing instead on organic growth [40] Question: Potential for loan yields to increase - Management indicated that there is potential for yields to improve as the pipeline yield increases and backflow repricing occurs [45] Question: Plans for geographic expansion - Management expressed interest in expanding into adjacent geographies, including Long Island and the Philadelphia suburbs, while already having teams in those areas [50]

Renasant (NYSE:RNST) Q4 2025 Earnings call January 28, 2026 10:00 AM ET Speaker8Good day, and welcome to the Renasant Corporation 2025 fourth quarter earnings conference call and webcast. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on a touch-tone phone. To withdraw your quest ...

CFO Mark Kaye reported adjusted diluted EPS of $3.33 for the fourth quarter and $30.29 for the full year. He said fourth-quarter results benefited from greater tax favorability than anticipated, increasing the full-year contribution from non-recurring items to $3.75 per share . Kaye added that solid underlying performance allowed the company to advance some investments originally planned for 2026 and to support workforce-related initiatives entering the year.Elevance Health established 2026 adjusted diluted ...

Financial Data and Key Metrics Changes - Central Bancompany reported a net income of $107.6 million, or $0.47 per fully diluted share, with a return on average assets of 2.17% [3] - The net interest margin on an FTE basis was 4.41%, and the efficiency ratio on an FTE basis was 47% [3] - Asset quality remained stable with net charge-offs at 10 basis points and an allowance covering 131 basis points of total loans [3] - Capital levels at the holding company were well above target, with approximately $1.8 billion of excess capital, equating to $7.50 per share [4] Business Line Data and Key Metrics Changes - The company experienced a 1% quarter-over-quarter increase in ending loans and a 1.7% increase in non-public deposits [4] - The wealth management segment saw assets under advice grow to $16 billion, driven by strong investment performance and net new money [36] - Treasury management initiatives showed some seasonality, with a noted falloff in payments volume in the fourth quarter [37] Market Data and Key Metrics Changes - The company noted a robust origination volume year-to-date in 2025, which was previously muted by higher levels of payoffs [16] - Non-public deposits grew by 1.7% in the quarter, with a year-over-year growth of approximately 6% [25] Company Strategy and Development Direction - M&A remains a core part of the company's strategy, with a focus on acquiring high-quality targets with approximately $2 billion in assets [9] - The company is looking to expand into Texas while continuing to grow in existing markets [9] - The management emphasized a disciplined approach to deploying excess capital, prioritizing M&A opportunities [27] Management Comments on Operating Environment and Future Outlook - Management expressed optimism about the resumption of balance sheet growth and the potential for continued loan growth, although they refrained from providing specific guidance [13] - The company is focused on maintaining consistent credit underwriting standards, regardless of market conditions [15] - Management indicated that they do not foresee significant changes in spreads for new loan production, maintaining around 300 basis points over comparable Treasuries [22] Other Important Information - The company achieved a Net Promoter Score improvement of 2 points to 73 across its business lines [3] - The management team highlighted the importance of community service, with over 28,000 hours contributed in 2025 [2] Q&A Session Summary Question: Update on M&A opportunities - Management confirmed that M&A is a core strategy, with ongoing discussions with potential targets and a focus on high-quality acquisitions [9][10] Question: Balance sheet growth pace - Management noted that loan growth was broad-based and indicated that customer demand will dictate future growth [13][15] Question: Spreads on new loan production - Management reported no spread compression and maintained spreads around 300 basis points over Treasuries [22] Question: Seasonal impact on deposit growth - Management acknowledged that a portion of deposit growth was seasonal due to property tax collections but emphasized overall strong growth [25] Question: Capital deployment post-IPO - Management reiterated that M&A opportunities are the primary focus for deploying excess capital raised during the IPO [27] Question: Wealth and treasury management growth - Management reported growth in assets under advice and ongoing investments in treasury management to sustain historical growth rates [36][37] Question: Credit portfolio health - Management indicated that there are no significant weaknesses in the credit portfolio, with a stable net charge-off rate [52][53]

Halifax, Nova Scotia--(Newsfile Corp. - January 26, 2026) - Torrent Capital Ltd. (TSXV: TORR) ("Torrent" or the "Company") today announced its preliminary, unaudited financial results for the fourth quarter ended December 31, 2025. At quarter end, the Company reported a Net Asset Value ("NAV") of approximately $32.4 million, or approximately $0.85 per share.Q4 and Year-End 2025 Preliminary Financial Highlights (Unaudited)Net Asset Value: NAV as of December 31, 2025 of $32.4 million (or $0.85 per share) com ...

Core Viewpoint - Roper Technologies, Inc. is a diversified technology company with a market cap of $48.5 billion, focusing on vertical software and technology-enabled products across various sectors [1] Financial Performance - Analysts project Roper to report an adjusted EPS of $5.13 for fiscal Q4 2025, reflecting a 6.7% increase from $4.81 in the same quarter last year [2] - For fiscal 2025, the expected adjusted EPS is $19.93, an 8.9% increase from $18.31 in fiscal 2024 [3] - Despite reporting a Q3 2025 adjusted EPS of $5.14, shares fell by 5.7% on October 23, with full-year 2025 DEPS guidance narrowed to $19.90 - $19.95 [5] Stock Performance - Roper's shares have decreased by 13.8% over the past 52 weeks, underperforming the S&P 500 Index, which gained 15.8%, and the State Street Technology Select Sector SPDR ETF, which surged by 23.2% [4] Analyst Sentiment - The consensus view on ROP stock is moderately optimistic, with a "Moderate Buy" rating; 11 out of 18 analysts recommend a "Strong Buy," five suggest "Holds," and two recommend "Strong Sells" [6] - The average analyst price target for Roper Technologies is $569.53, indicating a potential upside of 26.3% from current levels [6]

Summary of Conference Call Company Overview - The conference was held at the Piper Sandler Healthcare Conference featuring Doretta Mistras (CFO) and Philippe Martin (Chief R&D Officer) of the company [1][2] Capital Deployment Strategy - The company maintains a balanced capital allocation philosophy, aiming for a 50/50 split between capital deployment and capital return over a three to five-year period [2] - In the current year, the focus has been on capital returns, particularly share buybacks, due to operational circumstances and stock price considerations [2] - The company is actively pursuing innovative, branded, patent-protected assets to enhance near-term revenue and EBITDA growth, particularly in the US [3] R&D Focus - The current strategy emphasizes commercial-stage assets, with a focus on late-stage products like Cenerimod and Selatogrel [5] - Cenerimod is undergoing two large Phase III studies for systemic lupus erythematosus (SLE), with OPUS-2 fully enrolled and OPUS-1 expected to follow shortly [7] - The drug is positioned to be used alongside standard treatments without adding safety concerns, targeting a significant unmet need in SLE and lupus nephritis [8][15] Clinical Trials and Market Positioning - The Phase III trials for Cenerimod are designed to account for previous learnings, particularly focusing on patients with high interferon I levels, which showed the greatest treatment effect [9] - The company is optimistic about the potential of Cenerimod in lupus nephritis, having received positive feedback from regulatory bodies [11][12] - Selatogrel's Phase III global program for acute myocardial infarction is progressing well, with nearly 1,000 patients enrolled per month and full enrollment expected by the end of the year [16] Fast-Acting Meloxicam Product - The company is preparing for a pre-NDA meeting with the FDA to discuss filing and potential for accelerated review [20] - The fast-acting meloxicam product targets over 80 million acute pain cases annually, with a focus on outpatient and ambulatory surgical centers [22] - The product aims to provide a non-opioid alternative in a market where over 50% of acute pain cases still rely on opioids [22] Market Differentiation and Pricing Strategy - The company is exploring pricing strategies and market access for the fast-acting meloxicam, aiming for a balance between value proposition and broad patient access [24] - The product is expected to have a minimum of three years of exclusivity through the 505(b)(2) pathway, with ongoing efforts to extend this exclusivity [28] Presbyopia Opportunity - The company sees a significant market opportunity in presbyopia, with over 90% of adults over 45 affected, and aims to differentiate its product through a unique mechanism of action that avoids common side effects associated with other treatments [30][32] Enterprise-Wide Strategic Review - An enterprise-wide strategic review is underway to enhance long-term sustainable revenue and EBITDA growth, focusing on various operational aspects including R&D, manufacturing, and commercial infrastructure [34] Conclusion - The company is strategically positioned to leverage its R&D pipeline and capital deployment strategy to drive growth and address unmet medical needs across various therapeutic areas [34]